JP2009545609A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009545609A5 JP2009545609A5 JP2009522936A JP2009522936A JP2009545609A5 JP 2009545609 A5 JP2009545609 A5 JP 2009545609A5 JP 2009522936 A JP2009522936 A JP 2009522936A JP 2009522936 A JP2009522936 A JP 2009522936A JP 2009545609 A5 JP2009545609 A5 JP 2009545609A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- agonist
- chemotherapeutic agent
- tumor
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 claims description 33
- 239000000556 agonist Substances 0.000 claims description 31
- 229940127089 cytotoxic agent Drugs 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 27
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 108010091477 IRL 1620 Proteins 0.000 claims description 10
- 229930012538 Paclitaxel Natural products 0.000 claims description 10
- DXPHNGAMYPPTBJ-TZMIJSMNSA-N irl 1620 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CCC(O)=O)C(C)C)C1=CN=CN1 DXPHNGAMYPPTBJ-TZMIJSMNSA-N 0.000 claims description 10
- 229960001592 paclitaxel Drugs 0.000 claims description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 10
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 8
- 229960004679 doxorubicin Drugs 0.000 claims description 8
- 229960002949 fluorouracil Drugs 0.000 claims description 8
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 5
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 5
- 102000006992 Interferon-alpha Human genes 0.000 claims description 5
- 108010047761 Interferon-alpha Proteins 0.000 claims description 5
- 102000003996 Interferon-beta Human genes 0.000 claims description 5
- 108090000467 Interferon-beta Proteins 0.000 claims description 5
- 102000008070 Interferon-gamma Human genes 0.000 claims description 5
- 108010074328 Interferon-gamma Proteins 0.000 claims description 5
- 102000000588 Interleukin-2 Human genes 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 101710205037 Sarafotoxin Proteins 0.000 claims description 5
- 229940009456 adriamycin Drugs 0.000 claims description 5
- 230000036770 blood supply Effects 0.000 claims description 5
- 229940127093 camptothecin Drugs 0.000 claims description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 5
- 229960004562 carboplatin Drugs 0.000 claims description 5
- 190000008236 carboplatin Chemical compound 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
- 229960000975 daunorubicin Drugs 0.000 claims description 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 5
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 5
- 229940044627 gamma-interferon Drugs 0.000 claims description 5
- 229960004768 irinotecan Drugs 0.000 claims description 5
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 5
- 229960000303 topotecan Drugs 0.000 claims description 5
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 5
- 108050009340 Endothelin Proteins 0.000 claims description 4
- 102000002045 Endothelin Human genes 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000029610 breast phyllodes tumor Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000023958 prostate neoplasm Diseases 0.000 claims description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- KIYSPBOGUDIMPC-SCGUGKIPSA-N 4-ala-endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)OC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)OC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(C)C)C1C=NC=N1 KIYSPBOGUDIMPC-SCGUGKIPSA-N 0.000 description 1
- -1 docetacel Chemical compound 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/461,961 US20070032422A1 (en) | 2002-10-24 | 2006-08-02 | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| PCT/US2007/074036 WO2008016793A2 (en) | 2006-08-02 | 2007-07-20 | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009545609A JP2009545609A (ja) | 2009-12-24 |
| JP2009545609A5 true JP2009545609A5 (https=) | 2011-07-28 |
Family
ID=38752363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009522936A Pending JP2009545609A (ja) | 2006-08-02 | 2007-07-20 | 癌の治療に寄与する方法、組成物および製造物品 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20070032422A1 (https=) |
| EP (2) | EP2450037A1 (https=) |
| JP (1) | JP2009545609A (https=) |
| KR (1) | KR101507178B1 (https=) |
| CN (1) | CN101522186B (https=) |
| AR (1) | AR062177A1 (https=) |
| BR (1) | BRPI0715521A2 (https=) |
| CA (1) | CA2658340C (https=) |
| DK (1) | DK2046323T3 (https=) |
| ES (1) | ES2402232T3 (https=) |
| IL (1) | IL196825A (https=) |
| MX (1) | MX2009001233A (https=) |
| NO (1) | NO20090915L (https=) |
| RU (1) | RU2407527C2 (https=) |
| TW (1) | TWI469776B (https=) |
| WO (1) | WO2008016793A2 (https=) |
| ZA (1) | ZA200900017B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
| US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| BRPI0722292A2 (pt) | 2006-08-31 | 2014-04-15 | Spectrum Pharmaceuticals Inc | Sensibilização de células de tumor à terapia com radiação pela administração de agonistas de endotelina |
| PL2182977T4 (pl) * | 2007-08-21 | 2017-01-31 | Midwestern University | Kompozycje do leczenia udaru lub incydentów mózgowo-naczyniowych za pomocą agonisty receptora endoteliny B |
| US9308235B2 (en) | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
| JPWO2017191843A1 (ja) * | 2016-05-06 | 2019-04-04 | 一般財団法人バイオダイナミックス研究所 | 高分子化薬物含有医薬組成物 |
| KR20260005957A (ko) * | 2023-04-26 | 2026-01-12 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | 폴리펩티드 및 이의 응용 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5550110A (en) | 1992-04-22 | 1996-08-27 | Warner-Lambert Company | Endothelin Antagonists II |
| CA2135151A1 (en) | 1993-11-08 | 1995-05-09 | Mitsuhiro Wakimasu | Cyclic hexapeptides, their production and use |
| US5811416A (en) | 1994-06-06 | 1998-09-22 | Board Of Regents The University Of Texas System | Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| WO1996019233A2 (en) | 1994-12-12 | 1996-06-27 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| US6251861B1 (en) | 1996-06-27 | 2001-06-26 | Takeda Chemical Industries, Ltd. | Treatment of cerebral infarction using cyclic hexapeptides |
| CA2268640A1 (en) | 1998-04-14 | 1999-10-14 | Mitsuru Shiraishi | Composition for preventing or treating ischemic disease |
| ATE225655T1 (de) | 1998-09-25 | 2002-10-15 | Warner Lambert Co | Chemotherapie des krebses mit acetyldinalin in verbindung mit gemcitabin, capecitabin oder cisplatin |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| US6545048B1 (en) * | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| JP2003535061A (ja) | 2000-05-31 | 2003-11-25 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | エンドセリン受容体拮抗剤および疼痛軽減特性を有する抗癲癇化合物または鎮痛剤の複合物 |
| WO2002049630A2 (en) | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Method for preventing or treating pain by administering an endothelin antagonist |
| WO2003009805A2 (en) | 2001-07-23 | 2003-02-06 | Brigham And Women's Hospital, Inc. | Analgesic methods using endothelin receptor ligands |
| US7973064B2 (en) | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
| US20030229004A1 (en) | 2002-03-20 | 2003-12-11 | Pangene Corporation | Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors |
| CA2502848C (en) | 2002-10-24 | 2012-10-02 | The Board Of Trustees Of The University Of Illinois | Use of irl-1620 and paclitaxel for preventing and treating breast tumors |
| US8217010B2 (en) | 2002-10-24 | 2012-07-10 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
| US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| US8980222B2 (en) | 2004-11-22 | 2015-03-17 | The Board Of Trustees Of The University Of Illinois | Diagnostic use of endothelin ETB receptor agonists and ETA receptor antagonists in tumor imaging |
| CA2598439A1 (en) * | 2005-02-22 | 2006-08-31 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
| BRPI0722292A2 (pt) | 2006-08-31 | 2014-04-15 | Spectrum Pharmaceuticals Inc | Sensibilização de células de tumor à terapia com radiação pela administração de agonistas de endotelina |
-
2006
- 2006-08-02 US US11/461,961 patent/US20070032422A1/en not_active Abandoned
-
2007
- 2007-07-20 BR BRPI0715521-2A patent/BRPI0715521A2/pt not_active IP Right Cessation
- 2007-07-20 KR KR1020097001590A patent/KR101507178B1/ko not_active Expired - Fee Related
- 2007-07-20 RU RU2009107085/14A patent/RU2407527C2/ru not_active IP Right Cessation
- 2007-07-20 DK DK07799742.7T patent/DK2046323T3/da active
- 2007-07-20 MX MX2009001233A patent/MX2009001233A/es active IP Right Grant
- 2007-07-20 JP JP2009522936A patent/JP2009545609A/ja active Pending
- 2007-07-20 CA CA2658340A patent/CA2658340C/en active Active
- 2007-07-20 WO PCT/US2007/074036 patent/WO2008016793A2/en not_active Ceased
- 2007-07-20 EP EP12153542A patent/EP2450037A1/en not_active Withdrawn
- 2007-07-20 ES ES07799742T patent/ES2402232T3/es active Active
- 2007-07-20 EP EP07799742A patent/EP2046323B1/en not_active Not-in-force
- 2007-07-20 CN CN2007800288089A patent/CN101522186B/zh not_active Expired - Fee Related
- 2007-08-01 TW TW96128166A patent/TWI469776B/zh not_active IP Right Cessation
- 2007-08-01 AR ARP070103398A patent/AR062177A1/es not_active Application Discontinuation
-
2009
- 2009-01-05 ZA ZA200900017A patent/ZA200900017B/xx unknown
- 2009-02-01 IL IL196825A patent/IL196825A/en not_active IP Right Cessation
- 2009-02-20 US US12/390,376 patent/US8030278B2/en not_active Expired - Lifetime
- 2009-02-27 NO NO20090915A patent/NO20090915L/no not_active Application Discontinuation
-
2011
- 2011-08-29 US US13/220,358 patent/US8440620B2/en not_active Expired - Fee Related
-
2012
- 2012-12-11 US US13/711,519 patent/US8729023B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bailly et al. | Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times | |
| Nowak et al. | Systemic therapy for advanced hepatocellular carcinoma: a review | |
| Zhang et al. | Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors | |
| Fazio et al. | Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view | |
| JP2009545609A5 (https=) | ||
| Albany et al. | Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine | |
| JP2019521180A5 (https=) | ||
| Ajani et al. | A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma | |
| JP2013503174A5 (https=) | ||
| WO2009120697A4 (en) | Method and compositions for treatment of cancer | |
| JP2013504582A5 (https=) | ||
| US20240091196A1 (en) | Use of trans-[tetrachlorobis(1h-indazole)ruthenate(iii)] for the treatment of cancer | |
| WO2014059199A1 (en) | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence | |
| RU2009107085A (ru) | Способы, композиции и изделия, способствующие лечению рака | |
| JP2011503039A5 (https=) | ||
| O'Dwyer | Multifaceted approach to the treatment of bcr-abl-positive leukemias | |
| JP2019507166A5 (https=) | ||
| Kaur et al. | Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs | |
| Li et al. | A multi-targeted tyrosine kinase inhibitor lenvatinib for the treatment of mice with advanced glioblastoma | |
| Sun et al. | Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells | |
| JP2010502638A5 (https=) | ||
| Kunisaki et al. | Biweekly Docetaxel and S-1 combination chemotherapy as first-line treatment for elderly patients with advanced gastric cancer | |
| Alkafaas et al. | DEXAMETHASONE IMPROVES THE RESPONSIVENESS OF HEPATOMA CELLS FOR BOTH FREE AND SOLVENT CONTAINING PACLITAXEL IN VITRO. | |
| Liu et al. | Gemcitabine plus anlotinib is effective and safe compared to gemcitabine plus docetaxel in advanced soft tissue sarcoma | |
| Park et al. | Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes |